Tech Company Financing Transactions

Aduro BioTech Funding Round

Foresite Capital, Morningside Group and OrbiMed invested in a $51.4 million funding round for Aduro BioTech. The round was announced on 12/31/2014.

Transaction Overview

Company Name
Announced On
Transaction Type
Venture Equity
Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Mailing Address
740 Heinz Ave.
Berkeley, CA 94710
Email Address
Aduro Biotech is a clinical-stage cancer immunotherapy company, the company's lead candidate -- an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas.
Aduro BioTech LinkedIn Company Profile
Social Media
Aduro BioTech Company Twitter Account
Company News
Aduro BioTech News
Aduro BioTech on Facebook
Aduro BioTech on YouTube

Management Team

Email & Social
Chief Executive Officer
Stephen Isaacs
  Stephen Isaacs LinkedIn Profile  Stephen Isaacs Twitter Account  Stephen Isaacs News  Stephen Isaacs on Facebook
Chief Medical Officer
Natalie Sacks
  Natalie Sacks LinkedIn Profile  Natalie Sacks Twitter Account  Natalie Sacks News  Natalie Sacks on Facebook
Chief Operating Officer
Gregory Schafer
  Gregory Schafer LinkedIn Profile  Gregory Schafer Twitter Account  Gregory Schafer News  Gregory Schafer on Facebook
Chief Operating Officer
Hans van Eenennaam
  Hans van Eenennaam LinkedIn Profile  Hans van Eenennaam Twitter Account  Hans van Eenennaam News  Hans van Eenennaam on Facebook
Chief Scientific Officer
Andrea van Elsas
  Andrea van Elsas LinkedIn Profile  Andrea van Elsas Twitter Account  Andrea van Elsas News  Andrea van Elsas on Facebook
Vice President
Anne Moon
  Anne Moon LinkedIn Profile  Anne Moon Twitter Account  Anne Moon News  Anne Moon on Facebook
VP - Bus. Development
Aimee Murphy
  Aimee Murphy LinkedIn Profile  Aimee Murphy Twitter Account  Aimee Murphy News  Aimee Murphy on Facebook
VP - Finance
Jennifer Lew
  Jennifer Lew LinkedIn Profile  Jennifer Lew Twitter Account  Jennifer Lew News  Jennifer Lew on Facebook
VP - General Counsel
Celeste Ferber
  Celeste Ferber LinkedIn Profile  Celeste Ferber Twitter Account  Celeste Ferber News  Celeste Ferber on Facebook
VP - General Counsel
Blaine Templeman
  Blaine Templeman LinkedIn Profile  Blaine Templeman Twitter Account  Blaine Templeman News  Blaine Templeman on Facebook
VP - Human Resources
Nancy Kaplan
  Nancy Kaplan LinkedIn Profile  Nancy Kaplan Twitter Account  Nancy Kaplan News  Nancy Kaplan on Facebook
VP - Operations
Quoc Le-Nguyen
  Quoc Le-Nguyen LinkedIn Profile  Quoc Le-Nguyen Twitter Account  Quoc Le-Nguyen News  Quoc Le-Nguyen on Facebook
VP - Operations
Aimee Murphy
  Aimee Murphy LinkedIn Profile  Aimee Murphy Twitter Account  Aimee Murphy News  Aimee Murphy on Facebook
VP - Operations
Justin Skoble
  Justin Skoble LinkedIn Profile  Justin Skoble Twitter Account  Justin Skoble News  Justin Skoble on Facebook
VP - R & D
Dirk Brockstedt
  Dirk Brockstedt LinkedIn Profile  Dirk Brockstedt Twitter Account  Dirk Brockstedt News  Dirk Brockstedt on Facebook
VP - Regulatory Affairs
Michele DeVries
  Michele DeVries LinkedIn Profile  Michele DeVries Twitter Account  Michele DeVries News  Michele DeVries on Facebook
VP - Regulatory Affairs
Sylvia Wheeler
  Sylvia Wheeler LinkedIn Profile  Sylvia Wheeler Twitter Account  Sylvia Wheeler News  Sylvia Wheeler on Facebook



Browse more venture capital transactions:

Prev: 12/31/2014: Just Push Pay venture capital transaction
Next: 12/31/2014: Solstice Biologics venture capital transaction


Share this article


Where The Data Comes From

Our team works diligently to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary